Longbio Pharma
Clinical trials sponsored by Longbio Pharma, explained in plain language.
-
New shot aims to control rare blood disease PNH
Disease control OngoingThis study tests an experimental drug called LP-005 in 30 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if LP-005 can lower a key blood marker (LDH) and raise hemoglobin levels, reducing the need for…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 17, 2026 07:34 UTC
-
New hive drug LP-003 passes first safety check in healthy volunteers
Disease control OngoingThis early-stage study tests a single dose of a new drug called LP-003 in 12 healthy adults to see if it is safe and how the body processes it. The drug is designed to help control chronic spontaneous urticaria (long-term hives). Participants are healthy volunteers aged 18 to 50.…
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
New allergy shot tested in teens: early safety check
Symptom relief OngoingThis early-stage study tests a new injection called LP-003 in 6 adolescents aged 12 to 18 with allergies like hay fever, asthma, or eczema. The main goal is to check safety and how the drug moves through the body. It is too early to know if it works, but results will guide future…
Phase: PHASE1, PHASE2 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated May 17, 2026 07:50 UTC
-
New shot aims to quiet stubborn seasonal allergies
Symptom relief OngoingThis study tests an injection called LP-003 in 546 adults with moderate to severe seasonal allergic rhinitis (hay fever) that standard treatments don't control well. Participants receive either the drug or a placebo, and researchers track how much their nasal symptoms (like sneez…
Phase: PHASE3 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated May 06, 2026 16:15 UTC